<DOC>
	<DOCNO>NCT02129634</DOCNO>
	<brief_summary>Background - In patient critical limb ischaemia ( CLI ) , infragenicular artery often involve . Without revascularisation , amputation often imperative . There high technical success rate endovascular revascularisation infragenicular artery percutaneous transluminal angioplasty ( PTA ) , mid- long-term result disappointing restenosis frequently occur . Drug-eluting balloon ( DEB ) PTA show improve patency rate PTA coronary artery . Aim - To study result DEB-PTA compare conventional balloon CB-PTA treatment infragenicular lesion patient CLI . - To evaluate cost-effectiveness DEB-PTA versus CB-PTA patient critical limb ischemia ( CLI ) quantify incremental cost-effectiveness ratio ( ICER ) . Hypothesis - DEB PTA result improve patency rate compare CB-PTA treatment infragenicular arterial lesion patient CLI . - DEB-PTA cost-effective strategy patient CLI compare CB-PTA . Methodology Multi-center , prospective , randomise parallel-group trial . Patients eligible enrolment CLI least one infragenicular lesion maximal total lesion length 20cm . Randomisation perform 1:1 ratio either DEB-PTA CB-PTA . Patients assess prior directly intervention , 3 , 6 12 month Rutherford classification , ankle-brachial index , toe pressure adverse event . Duplex perform 3 month . Angiography perform directly PTA 6 month . Primary end-point primary patency treat lesion 6 month angiography ( define &lt; 50 % stenosis , without re-intervention interim ) . Secondary end-points limb salvage 3 , 6 12 month , primary patency treat lesion Duplex 3 month ( defined patency treat artery peak systolic velocity ( PSV ) ≤2.0 m/sec ) , Rutherford classification , minor major amputation , infrapopliteal endovascular re-intervention , patency treat femoropopliteal site ( applicable ) , infrapopliteal surgical bypass , peri-procedural complication death 3 , 6 12 month . A cost-effectiveness analysis ( CEA ) societal perspective perform parallel randomized clinical trial 12-month time horizon .</brief_summary>
	<brief_title>Singapore INfra-Genicular Angioplasty With PAclitaxel-eluting Balloon Critical Limb Ischaemia ( SINGA-PACLI ) Trial</brief_title>
	<detailed_description>Methodology 1 . Study design : This investigator-initiated multi-center , prospective , randomise , control , two-arm parallel-group study . The participate center Singapore General Hospital Tan Tock Seng Hospital . Patients eligible enrolment CLI least one infragenicular lesion maximal total lesion length 20cm . Randomisation perform 1:1 ratio either DEB PTA CB PTA . Patients assess prior directly intervention , 3 , 6 12 month Rutherford classification , ankle-brachial index , toe pressure adverse event . Duplex perform 3 month . Angiography perform directly PTA 6 month . Primary end-point primary patency treat lesion 6 month angiography ( define &lt; 50 % stenosis , without re-intervention interim ) . Secondary end-points limb salvage 3 , 6 12 month , primary patency treat lesion Duplex 3 month ( defined patency treat artery peak systolic velocity ( PSV ) ≤2.0 m/sec ) , Rutherford classification , minor major amputation , infrapopliteal endovascular re-intervention , patency treat femoropopliteal site ( applicable ) , infrapopliteal surgical bypass , peri-procedural complication death 3 , 6 12 month . A cost-effectiveness analysis perform alongside 3-year randomized clinical trial DEB PTA versus CB- PTA . Both cost utility outcomes determine data sample patient enrol study estimate use comparable time horizon . The time horizon economic analysis 12 month , patient 's study inclusion 12 month PTA . Analysis perform societal perspective . Direct healthcare non-health care cost incur presented 2013 Singapore dollar ( SGD ) . Hospitalization cost determine cumulative hospital billing data . Other healthcare cost outside SGH/TTSH indirect cost determine patient survey 3 , 6 , 12 month post-procedure . Information Qualify Life ( QoL ) measure use EQ-5D-3L ( baseline , 3 months- , 6 months- 12- month ) use calculate Quality-Adjusted Life Years ( QALY ) incorporate mortality . 2 . Participants : Patients critical limb ischaemia meet inclusion exclusion criterion enrol . Participation entirely voluntary eligible subject competent understand implication participation study . Informed consent form design assure protection patient 's right . Before enrolment patient give write informed consent . The centre 's local investigator ensure patient informed basis Informed Consent Form . 3 . Outcome Measurement ( 3.1 ) Primary outcome : Primary patency treat ( index ) site 6 month . Primary patency define less equal 50 % loss luminal diameter treat site angiography without re-intervention interim . ( 3.2 ) Secondary outcome : • Limb-salvage rate trial leg 3 , 6 12 month . • Primary patency duplex sonography treat ( index ) site 3 month . • Clinical categorisation treat ischemic leg mean Rutherford classification 3 , 6 12 month . • Minor amputation ( ankle exclude toe ) trial leg 3 , 6 12 month . • Infrapopliteal surgical bypass trial leg 3 , 6 12 month . • Infrapopliteal endovascular re-intervention trial leg 3 , 6 12 month . • Primary patency treat femoropopliteal site , applicable . • Peri-procedural ( within 30 day ) complication . • Death . • Incremental cost-effectiveness ratio ( ICER ) , i.e. , mean difference cost divide mean difference QALY 4 . Investigational product : ( 4.1 ) Paclitaxel : Paclitaxel inhibit SMC replication G2/M phase , SMC migration extracellular matrix formation , thus inhibit neointima formation . Neointima formation cause restenosis . ( 4.2 ) Drug elute balloon : A drug-eluting balloon ( DEB ) paclitaxel-coated peripheral angioplasty balloon catheter specifically design PTA small peripheral atherosclerotic obstruct artery . DEBs available different size 2mm , 2.5mm , 3mm , 3.5mm 4mm diameter 40mm , 80mm 120mm length . The DEBs coat proprietary hydrophilic formulation paclitaxel matrix substance . Paclitaxel coat DEB currently register Singapore use . Protocol 1 . Randomisation : Patients randomize either DEB-PTA CB-PTA lesion cross guidewire . The allocation ratio 1:1 . Randomization stratify diabetes renal failure status . Patients blind assigned treatment . The operator SGH TTSH site perform angioplasty angiogram procedure . The operator perform angiogram 6 month follow-up blind treatment arm prevent bias . For read image , radiologist read image also blind prevent bias . 2 . Procedure Following antegrade retrograde femoral puncture insertion arterial sheath haemostatic valve , angiography perform . Angiographic feature lesion ( ) assess . If endovascular treatment consider feasible , patient exclude study . The lesion cross fluoroscopic guidance combination catheter guidewire accord choice operator . Following lesion cross patient randomise receive either DEB-PTA CB-PTA . If crossing lesion unsuccessful , patient randomize . ( 3 ) DEB-PTA arm After successful cross target lesion , angioplasty conventional angioplasty balloon perform DEB-PTA . A conventional angioplasty balloon diameter 0.5mm less intend DEB balloon advance guidewire inflate trial lesion site , accord normal practice operator . A DEB diameter match target vessel lesion length advance 0.018 inch guidewire inflate target lesion site 60 second . If lesion length longer length balloon , second inflation another DEB require . The maximal total lesion length treat lesion exceed 20cm , maximal length treat two DEBs . Comparisons pre- post-implantation percent stenosis make angiographic projection ( ) . Whenever stent placement require 'bail-out ' case post-PTA occlusion flow-limiting dissection , bare metal ( non-drug eluting ) stent use . ( 4 ) CB-PTA arm After successful cross target lesion , conventional angioplasty balloon diameter match target vessel advance guidewire inflate target lesion site , accord normal practice operator . Comparisons pre- post-implantation percent stenosis make angiographic projection ( ) . Whenever stent placement require 'bail-out ' case post-PTA occlusion flow-limiting dissection , bare metal ( non-drug eluting ) stent use . ( 5 ) Morphologic lesion classification : Morphologic lesion classification angiography perform accord Transatlantic Intersociety Consensus ( TASC ) document management peripheral arterial disease : TASC Type A infrapopliteal lesion : 1 . Single stenoses short 1 cm tibial peroneal vessel . TASC Type B infrapopliteal lesion : 2 . Multiple focal stenosis tibial peroneal vessel , less 1 cm length . 3 . One two focal stenosis , less 1 cm long , tibial trifurcation . 4 . Short tibial peroneal stenosis conjunction femoropopliteal PTA . TASC Type C infrapopliteal lesion : 5 . Stenoses 1-4 cm length . 6 . Occlusions 1-2 cm length tibial peroneal vessel . 7 . Extensive stenosis tibial trifurcation . TASC Type D infrapopliteal lesion : 8 . Tibial peroneal occlusion longer 2 cm . 9 . Diffusely diseased tibial peroneal vessel . TASC classification do investigational purpose influence treatment study . ( 6 ) The following information relate procedure collect : - General participant demographic ( initial , subject-number , date birth , gender ) - Number lesion - Location lesion - TASC morphology classification - Contrast medium type amount administer - Type size sheath , guidewires catheter - Diameters non-diseased arterial lumen proximal distal target site treat lesion - Percentage stenosis lesion treatment lesion - Lesion length prior treatment treated lesion - Quality runoff ( number vessel presence stenoses occlusion ) distal target site treatment - Type , size , length number balloon used/ Numbers stent use - Presence absence complication - Use closure-device ( use , type ) ( 7 ) Escape procedure : In case stent placement require treat dissection proximal , distal site treat lesion , operator must consider best interest patient . Patients receive bare metal ( non-drug eluting ) stents 'bail-out ' stenting require due post-PTA occlusion flow-limiting dissection , common practice . In case acute arterial thrombosis embolism , table infusional thrombolysis ( use urokinase rTPA ) mechanical thrombectomy permit accord preference operator local hospital protocol . ( 8 ) End procedure The procedure consider complete delivery material include catheter sheath introducer remove . ( 9 ) Anti-platelet medication The following anti-thrombotic medication administer . - During procedure , least 2000 unit heparin administer intravenously intra-arterially . If necessary dose may increase repeated case prolong procedure - Overnight treatment heparin permit - Clopidogrel 75 mg daily administer least 6 month follow procedure - Aspirin 100 mg daily administer least 12 month follow procedure . Follow Up All patient evaluate prior hospital discharge , 3 month ( ± 14 day ) , 6 month ( ± 14 day ) 12 month ( ± 30 day ) post-procedure , upon return complaint . All patient follow 12 month follow-up period . They see duplex sonography 3 month upon return complaint . Angiography perform 6 month . All report AEs SAEs followed-up close . SCRI keep electronic SAE track log SCRI track report SAEs . This ensure SAE follow resolve report accredited IRB .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Written inform consent Age &gt; 21 year If female patient child bear potential , patient may pregnant study entry must utilize reliable birth control duration participation study Patient willing able comply specify followup evaluation Critical Limb Ischaemia , Rutherford category 4 ( ischaemic rest pain ) , 5 ( minor tissue loss ) 6 ( major tissue loss ) Stenosis ( &gt; 50 % luminal loss ) occlusion infragenicular artery ( define : distal infrapopliteal artery ) , include tibiofibular trunk , anterior tibial artery , posterior tibial artery peroneal artery Infragenicular arterial lesion length &lt; 20cm At least one crural ( anterior tibial , posterior tibial peroneal ) artery expect unobstructed runoff ankle level treatment Successful guidewire cross trial lesion Acute limb ischaemia Subacute limb ischaemia require thrombolysis first treatment modality Previous major amputation affect limb ( level ankle ) Concurrent iliac femoropopliteal artery disease suitable endovascular surgical revascularisation Concurrent iliac femoropopliteal artery occlusion &gt; 10cm , even suitable surgical endovascular revascularization Patients without ( expect ) distal runoff index site Revascularization involve site within 30 day prior index procedure plan revascularization limb within 30 day index procedure Previous implant stent index site Life expectancy le 6 month Factors make clinical followup difficult impossible Known allergy paclitaxel Known allergy contrast medium Patients Warfarin anticoagulant Known allergy antiplatelet drug ( Aspirin/ Clopidogrel ) ( ) unable tolerate dual antiplatelet drug therapy Active history gastritis bleed tendency preclude use dual antiplatelet therapy Known heparin induce thrombocytopenia ( HIT type 2 ) Patient unable unwilling tolerate contrast medium eGFR less 50 ml/min/1.73m2 unless patient dialysis . If patient significant heart disease Left Ventricular Ejection Fraction Percentage ( LVEF % ) less 35 % . Either PT/PTT &gt; 1.5 time median normal correct time procedure ( ) INR &gt; 1.6 correct time procedure Thrombocytopenia platelet count &lt; 50,000 /µL ( 50 X 109/L ) correct time procedure</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Percutaneous Transluminal Angioplasty</keyword>
	<keyword>Limb-salvage</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>